The authors attempted to investigate clinical parameters and genetic variations linked to diabetic kidney disease (DKD) in a population of Arab descendants from the United Arab Emirates (UAE). Based on their data, Osman et al. demonstrated that several genetic loci, including SHROOM3, significantly correlated with indicators for kidney function. Considering higher prevalence of NIDDM in UAE population, the topic is of interest to improve morbidity and mortality in DKD patients. The methods seem to be appropriate, and the Discussion section is supported by their results and previous reports. However, I have some interests and concerns in this study.
Major comment 1) As the authors mentioned in the Discussion, multiple complex pathogenesis for each patient in DKD are considered to affect the profiles of gene expression. How are the screened genetic loci working in the pathogenesis of DKD? Would it be possible to demonstrate further molecules and transcriptional factors related to the screened genetic loci in the present study? 2) In clinical setting, multiple reagents for renal protection in DKD patients are used in combination. Do the gene expression profiles depend on individual reagents? 3) Several studies exploring and validating the role of SHROOM3 are thus preformed (J Am Soc Nephrol. 2016, 27(10): 2965-2973; Pharmacogenet Genomics. 2017, 27(1): 19-26; PLoS One. 2017, 12(10): e0185476). In brief, SHROOM3 appears to maintain podocyte architecture through the regulation of the actomyosin network. The authors had better document the role of each genetic factor such as SHROOM3 in the Discussion section.
1. You have reported P-values for SNPs and clinical prognostic factors in your tables. However it is unclear whether you have corrected for multiple comparisons, given the number of genotype and the number of phenotype in your analysis, To clarify this, you may describe the methods used to correct for multiple comparisons, and to control for risk of false-positive findings In Methods section, 2. Page 7, Lines 147 -152, You may clarify your study sample by adding years of diagnosis of patients, names of hospitals or names of communities (sampling frame), and nonresponse rates, etc.. 5. Unclear whether the study has taken into account treatments in your adjusted logistic analyses. Are cases and controls comparable in terms of treatments ?
6. Table 4 . The footnote: "Beta: regression coefficients for interaction in the linear regression model". In Methods section, you may clarify how this interaction was carried out. Gene-gene interaction or gene-environment interaction, etc.?
7. Page 13. Table 1 . You may add footnotes for "reported" and "tested" to make the table self-explanatory.
Minors: 8. Page 9, Line 150.. You may clarify "R2" and "D'". It is inappropriate to assume all readers know these parameters. Also, you need to provide the rationale to choose proxy SNPs. 9. Page 5, Line 85. "rate" may be changed to "prevalence"
REVIEWER
Tony Fitzgerald University College Cork, Ireland REVIEW RETURNED 14-May-2018
GENERAL COMMENTS
Given my delay in providng my review I will keep my comments brief. My review will focus on the statistical methods. 6. The authors refer to patients and controls when referring to those with/without CKD. All subjects were patients so they need to revise this.
7. Text needs revision (line 240) so that it states that those with CKD were more likely to be male than those without CKD.
8. The authors refer to 'risk factors for the development of CKD' (page 11 in particular). Given that the study is cross-sectional they can only establish that factors are associated with CKD.
9. The answer for this comment is quite difficult as there are not enough studies to prove the hypothesis, but theoretically we believe the answer is yes. Drugs and other natural reagents (such as Gum Arabic or Grape seed powder) will eventually lead to reduce the inflammatory markers or the oxidative stress, and improve the renal function readings in patients with DKD, which will lead to reduce the expression of some of the genes controlling these processes. The extent of this expression level is not known. As we performed genetic association analyses, we did not discuss the gene expression point in this study. We also refer to the point that reagents were used in adjustment in our logistic models in lines 460-462 in page 28. Same drugs response was also mentioned in our response to comment #5, reviewer #3; Dr. Dong Pang. We also added this sentence as in lines 129-130, page 7 as Dr. Alicic suggested "In spite of efforts to describe novel biomarkers for DKD, no tested candidates outperform albumin". Regarding reporting the clinical and laboratory risk factors comments this study was initially designed on a candidate gene approach and after reporting the results we designed the 2nd phase of the study, which to conduct a larger GWAS study that will include the reporting clinical and laboratory risk factors and it would be a follow up after this manuscript. Response: This is because DKD development is known to be influenced by these extra factors. For example, hypertension is known to be both a risk and consequence of chronic kidney disease (PMID: 20979962). It is also known that dyslipidemia (so called renal dyslipidemia) can lead to a proinflammatory condition, which can result in renal endothelial dysfunction and vascular damage (PMID: 19512921). So to avoid bias, we included all factors which may lead to the development of the DKD. Age and gender are frequently used to adjust for genetic associations of renal function traits (PMIDs: 19430482, 20383146, 20383145, and 22479191).
5. Both ACR and eGFR are used to define DKD. How is evaluating ACR, eGFR, creatinine, and SNP correlation different from evaluating DKD and SNP association? Response: Up-to-date, there is no single genetic variation found to predict the susceptibility of the DKD superior to ACR, eGFR, and creatinine measures. However, because these measures are affected by the responses to different pharmacological factors not like the genetic variation, genetic variations will be better in predicting future/susceptible patients superior to these agent. In the current study, this is also the case, the lab markers are superior to the genetic associations in defining DKD.
6. If association of the SNP/loci with DKD /CKD already established are authors confirming this association in the tested population?
Response: Yes, all these loci were reported in different populations, and we here try to replicate them in the Arab population. To clarify this, we add this sentence to the methods section "Genetic studies in this study follow the candidate gene approach", line 178 in page 9. The study described in the manuscript is interesting because it has addressed an important issuethe genetic role in renal function and diabetic kidney disease in Emirati patients with T2DM. It appears that the study has been carried out effectively. However I have major comments, in particular, statistical methods.
You have reported P-values for SNPs and clinical prognostic factors in your tables.
However it is unclear whether you have corrected for multiple comparisons, given the number of genotype and the number of phenotype in your analysis. To clarify this, you may describe the methods used to correct for multiple comparisons, and to control for risk of false-positive findings In Methods section. Response:
We first sincerely thank Dr. Pang for the critical revision and for his time. To refer to the issue of the multiple testing, we have added the following to the methods section "As this is a replication study, we reported here all P-values < 0.05, suggesting possible replications. However, using a Bonferroni correction for multiple testing, P-values with statistically significant associations are like the following: < 0.00079 for the DKD associations, < 0.0006 for the ACR, < 0.0005 for the Vitamin D, < 0.00017 for the eGFR, < 0.00019 for the creatinine, and 0.00068 for the urea associations. " (see lines 238-242 in page 12). We also added the following sentence in the results section "In summary, no association passed the Bonferroni correction for multiple testing. However, we report here the most suggestive associations which point to replications of previous reports" (see lines 334-336 in page 19).
2. Page 7, Lines 147 -152, You may clarify your study sample by adding years of diagnosis of patients, names of hospitals or names of communities (sampling frame), and nonresponse rates, etc.. Response:
In table 2, we mentioned about the diabetes duration in patients with or without DKD. As in the Methods section, all patients were recruited from Sheikh Khalifa Medical City (SKMC) and Mafraq Hospital, major tertiary hospitals in Abu Dhabi, UAE. Both hospitals used the same criteria for diagnosis and lab measurements, with except of albumin: creatinine ratio units (mg/mmol Mafraq and mg/gm in SKMC), most of the ACR which was used in this study were from Mafraq hospital.
3. Page 7, Line 147. "... prospective cross-sectional ..." Further clarification is required for "prospective".
Response:
We agree with Dr. Pang that the term prospective might be confusing. When we conducted this study we collected data for exposure and outcome information at the same time, and we did not request data from patients that happened several years ago (i.e. not retrospective approach). However, because the term might still be confusing, and because when reviewing articles in the BMJ Open website we found most of studies only use cross-sectional study, we deleted the word prospective from the revised manuscript. We are now refereeing to the current power in the Methods section, (see lines 243-251 in page 12), and in the "Strengths and limitations of this study" section part after the abstract.
5. Unclear whether the study has taken into account treatments in your adjusted logistic analyses. Are cases and controls comparable in terms of treatments? Response:
We did not included treatments in the logistic analyses due to the fact that both patients and controls are taking multiple drugs for different conditions (type 2 diabetes, dyslipidemia, and hypertension) in addition to other drugs like anti coagulants and other kidney disease therapies. Adjustment of several drug classes will lead to largely unstable logistic models and will make the interpretation of any results so difficult. In addition, nearly of 20% of patients have at least one missing information about the treatment they take, which we generate a bias. We acknowledge this might be a limitation, and we refer to this in the revised manuscript "The logistic analyses carried in this study did not included treatment modalities because most of patients have multiple conditions and their usage of several treatments, which make the logistic largely unstable and difficult to interpret", (see lines 465-467 in page 28).
6. Table 4 . The footnote: "Beta: regression coefficients for interaction in the linear regression model". In Methods section, you may clarify how this interaction was carried out. Gene-gene interaction or gene-environment interaction, etc.? Response:
We apologize for this mistake. The word interaction was mentioned incorrectly here, and we have deleted it from the revised manuscript.
7. Page 13. Table 1 . You may add footnotes for "reported" and "tested" to make the table selfexplanatory.
Response: We thank Dr. Pang for the suggestion. A footnote is now added to Table 1 .
Minors: 8. Page 9, Line 150. You may clarify "R2" and "D'". It is inappropriate to assume all readers know these parameters. Also, you need to provide the rationale to choose proxy SNPs. Response: R2 and D' are mathematical measures for what is called "linkage disequilibrium and abbreviated as LD" which indicates a non-random association of alleles (in this study SNPs) at different genetic loci in a given population. In other words, alleles in high LD (defined as R2 > 0.8) are tend to be inherited as a block, known as LD block, and D' used as indicator for it. Therefore, we have added the following explanation to the revised manuscript "Our search strategy consisted of identifying reported SNPs that cleared the GWAS significance-level and were found in our GWAS data. If the original signal SNP was missing from the GWAS data, we searched for a possible proxy SNP utilizing the concept of linkage disequilibrium (LD), which indicates a non-random association of alleles at different genetic loci in a given population and their tendency to be inherited as a block (mathematical values r2 and D' > 0.8 indicates high LD)" (see lines 190-195 in pages 9-10). Table 2 and in the footnotes and the Methods section as in line 222-224 in page 11 "For continuous data, statistical differences were assessed using two-sided t-tests for normally distributed data or Wilcoxon rank-sum (Mann-Whitney) test for highly skewed data".
6. The authors refer to patients and controls when referring to those with/without CKD. All subjects were patients so they need to revise this.
Response:
We agree that all patients are diagnose with T2D. We use patients here to refer to those who developed DKD and controls to those who did not. We updated the revised manuscript as (patients with DKD vs. patients without DKD) instead of patients vs. controls. 8. The authors refer to 'risk factors for the development of CKD' (page 11 in particular). Given that the study is cross-sectional they can only establish that factors are associated with CKD. Response: Concern has been addressed. We acknowledge that associations rather than risks should be used here. We updated this point wherever it is mentioned in the revised manuscript.
9. Table 3 is very confusing. It is not clear whether the risk factors listed were included individually or whether all were included. Clearly the latter option is not sensible but this need to be stated clearly in the table. For all the covariate the unit's would be included (as is done in earlier tables). The SEs and Z-statistics add nothing and should be removed.
Response: All risk factors were included in this logistic model for Table 4 to adjust for each other and get a true association, which is independent of all other factors. This is the reason why we tested the validity of the model first using Hosmer-Lemeshow goodness of fit test. This is also clearly mentioned in the revised manuscript as the following: "However, the logistic model which includes all the associated factors in Table 4… etc." see line 233 page 11. Also we have deleted the SEs and Z-statistics from Table 4 according to the suggestion.
10. When looking at genetic association with renal function associated traits, the authors should explain what is meant by the effect size. It appears to be nothing more than a difference in means. This also applies to the 'beta' in table 4. Response:
We agree this term might be confusing. Effect size here is used to indicate beta, and beta as mentioned in the footnote of Table 4 : Beta: regression coefficient for the linear regression model, calculated based on A1 (the minor allele). Also this comment lead us to discover that we did not mentioned anything about Table 4 in the methods, and therefore we updated the methods section in the revised manuscript to include the following: "Analyses between SNPs and renal function traits were conducted in PLINK using linear regression models that included age and gender as covariates. Results were presented as beta (regression coefficient for the linear regression model, calculated based on the minor allele), standard errors, and P-values" (see lines 234-237, pages 11-12).
11. In table 4, some of the p-values should be rounded e.g. 0.0030 to 0.003 and 0.0082 to 0.008. Response: Concern has been addressed.
VERSION 2 -REVIEW

REVIEWER
Tomoki Kosugi Nagoya University Graduate School of Medicine, Japan REVIEW RETURNED 22-Jul-2018
GENERAL COMMENTS
Thank you for inviting me as a reviewer in your journal.
Considering higher prevalence of NIDDM in UAE population, the topic is of interest to improve morbidity and mortality in DKD patients. The revised manuscript is improved and well documented along with the reviewers' comments.
I am looking forward to working with you in this journal. 
REVIEWER
